biomed devic servic
price close busi januari
invas medic devic heart valv therapi
includ tissu valv mechan valv
what store target
recommend investor continu overweight ew result portend robust
tavr trend continu least next quarter point tavr
franchis lap low-risk approv said acceler new center
add new import dynam impli us low double-digit tavr
growth estim could prove conserv notwithstand
daunt y/i comp wit ew ad new center believ
highest level new center add given quarter year notabl
ew use tavr-driven revenu upsid beat us total
tavr invest heavili field resourc larg us think
higher near-term invest wise ew activ augment tavr center
abil attract screen implant ssa patient therebi increas capac
reduc capac util ratio make centers/physician effici
suggest us ew us tavr busi solid foot sever
quarter higher spend mitig oper leverag higher
revenu guidanc tavr given ew drove increas ep guidanc
well demonstr leverag believ still exist model moreov
analysi suggest firm could ultim produc om higher
high-end new ep rang impli impli earn could exceed
book close base current estim
rais year-end target would stay buyer ew
what new/ matter
tavr tavr continu shine star edward gener annual
revenu repres y/i growth rate well surpass
ew guidanc expect enter year stellar
perform us tavr volum grow approxim in-
line overal domest market acceler fda approv tavr
low surgic risk patient past summer wit believ growth
buy pt made tavr market
period came expens rate roughli addit
tavr center came on-line period new center add
given quarter year accord model us market
serv center inde favor rule form
updat ncd last spring open tavr market estim site
least ew view could qualifi tavr center expect us market
reach center sometim center choos stock tavr
system howev new center add come form exclus
site albeit think except rule time manag
reiter confid continu growth tavr market view
market opportun despit clearli posit impact low-
risk approv manag note acceler procedur volum
driven patient span risk spectrum interest dynam
suggest elimin tavr risk stratif could greas skid
patient sever symptomat aortic stenosi ssa regardless whether
good candid surgeri edward roll manag
updat guidanc tavr growth top end forecast rang
imagin estim could prove conserv given aforement
dynam acceler new center add seemingli increas growth across
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
tmtt updat ew still earli inning push develop
market leader global transcathet mitral/tricuspid therapi market
full-year sale came origin guidanc
manag still feel confid estim
revenu long believ market theoret
bigger tavr also opin market take even longer
tavr tip ew reiter assumpt name tmtt
revenu exceed global think aggress
optimist ew inde highli instrument market
develop well key player drive long-term market
growth expect firm still track four pivot studi
space detail investor day decemb ew initi
enrol clasp iitr pivot trial studi pascal patient
symptomat sever tricuspid regurgit addit compani continu
make stride gain use experi cardioband tricuspid
system potenti paradigm-chang mitral repair system firm
focus develop approach next-gen version applic
broader rang physician expect tmtt revenu bounc back
follow voluntari field correct action relat pascal novemb
sale continu grow throughout
guidanc updat edward updat full year revenu
expect firm anticip total sale versu
previous firm also expect adjust ep rang
versu previous firm increas top-lin
growth expect stem continu tavr momentum tavr mix
support margin expans bottom-lin upsid well compani
expect tavr revenu growth high end forecast rang
manag continu expect adjust gross profit margin
sg expect sale
manag highlight need spend extra field personnel tavr
case high-touch model continu pick volum ew also
invest benchmark program firm instruct new center
best practic facilit continu improv patient outcom
expect firm continu invest new
technolog gener evid tavr tmtt guidanc
surgic structur heart critic care reiter
respect
sale trend tavr sale expect rel
sequenti stabl said continu believ law
larger number begin impact tavr growth profil especi
compani hit august anniversari low-risk approv
moreov expect tmtt continu see tremend
potenti long term appreci impact model
time-frame consequ keep eye potenti impend
lull top-lin growth time-frame tmtt grab
growth baton tavr
updat cash posit potenti continu edward
finish year cash balanc sheet addit firm
gener north adjust free cash flow firm continu
invest global suppli chain support growth also invest
extern strateg allianc purchas option acquisit
continu believ ew expand footprint beyond tradit
structur heart firm current back option acquir
heart failur play corvia novel iasd platform well
invest similar devic v-wave play space
bullish long term think ew could becom
buy unchang target price januari
biomed devic servic
acquisit go forward given strong cash flow solid balanc sheet
ep laac af addit hf repres potenti target expans
area would remain focus ew commentari around current
pipelin portfolio tmtt key gap firm see product today
area firm view promis tangenti adjac current focu
deriv price target appli price-to-earnings
pro forma ep estim
buy unchang target price januari
biomed devic servic
p/e/g valuat financi metric use median large-cap med-tech comp group price-to-earnings multipl forma ep growth forward p/e/g multipl price-to-earnings multipl forma mo lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market figur tavr us market model
buy unchang target price januari
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat tam ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun figur tavr us market share
buy unchang target price januari
biomed devic servic
edward lifesci implant averag implant total unit asp ew us revenu averag total unit asp us revenu averag total implants- implant unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavr eu/row market share
buy unchang target price januari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform
appear front page report
buy unchang target price januari
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model part
buy unchang target price januari
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid total tmvr/re total transcathet valv therapi surgic heart valv therapytissu repair surgic heart valv cardiac surgeri cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular vascular casm total critic vascular revenu pro forma total revenu figur revenu model part
buy unchang target price januari
biomed devic servic
